TickerFacts.

Organon & Co. (OGN): Cost of Revenue

Annual figures by period end, from SEC filings.

$2.90B
Year ended 2025-12-31
$2.90B
Trailing 12 months to 2026-06-30
+8.2%
3-year compound annual growth
+6.5%
5-year compound annual growth
2019-12-31: $2.27B2020-12-31: $2.12B2021-12-31: $2.38B2022-12-31: $2.29B2023-12-31: $2.52B2024-12-31: $2.69B2025-12-31: $2.90B$2.90B
2019-12-31 Cost of Revenue (USD) 2025-12-31
Period endedCost of RevenueChange YoYSource filing
2025-12-31$2.90B+8.0%2026-02-24, From 2025-01-01
2024-12-31$2.69B+6.9%2026-02-24, From 2024-01-01
2023-12-31$2.52B+9.6%2026-02-24, From 2023-01-01
2022-12-31$2.29B-3.7%2025-11-10, From 2022-01-01
2021-12-31$2.38B+12.4%2024-02-26, From 2021-01-01
2020-12-31$2.12B-6.8%2023-02-27, From 2020-01-01
2019-12-31$2.27Bn/a2022-03-21, From 2019-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
Organon & Co. (OGN)2025-12-31$2.90B+8.0%
Elanco Animal Health Inc (ELAN)2025-12-31$2.12B+5.9%
Perrigo Co PLC (PRGO)2025-12-31$2.76B-2.5%
Zoetis Inc. (ZTS)2025-12-31$2.67B-1.9%
Alnylam Pharmaceuticals, Inc. (ALNY)2025-12-31$677.17M+120.9%
BioMarin Pharmaceutical Inc (BMRN)2025-12-31$717.44M+23.6%
Vertex Pharmaceuticals Inc (VRTX)2025-12-31$1.65B+7.9%
United Therapeutics Corp (UTHR)2025-12-31$384.40M+24.1%
Amneal Pharmaceuticals, Inc. (AMRX)2025-12-31$1.91B+7.4%

Compare OGN, ELAN, PRGO, ZTS side by side · Screen every company in Pharmaceutical Preparations ↗